SCHEMBL3634007

SCHEMBL3634007

CCOC(=O)C1(CI)CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.37
USP2 O75604 1/20 0.37
NR1H2 P55055 2/20 0.36
ADORA1 P30542 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
ALDH1A1 P00352 2/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
TSHR P16473 1/20 0.33
EPHX2 P34913 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25245654 0.88 SMN1; SMN2 (0.42) SMN1; SMN2USP2NR1H2ADORA1L3MBTL1
SCHEMBL12543830 0.87 L3MBTL1 (0.45) L3MBTL1MEN1KMT2AALDH1A1NPC1
SCHEMBL3629291 0.87 NR1H2 (0.40) SMN1; SMN2USP2NR1H2ADORA1L3MBTL1
SCHEMBL6188518 0.86 USP2 (0.42) SMN1; SMN2USP2ADORA1L3MBTL1CYP4F2
SCHEMBL3634028 0.85 L3MBTL1 (0.40) SMN1; SMN2USP2NR1H2ADORA1L3MBTL1
SCHEMBL22233140 0.85 ADORA1 (0.39) SMN1; SMN2USP2NR1H2ADORA1L3MBTL1
SCHEMBL426525 0.81 SMN1; SMN2 (0.41) SMN1; SMN2USP2NR1H2ADORA1MEN1
SCHEMBL22233978 0.81 ALDH1A1 (0.34) SMN1; SMN2USP2NR1H2ADORA1L3MBTL1
SCHEMBL13118618 0.80 CYP4F2 (0.44) SMN1; SMN2USP2ADORA1L3MBTL1CYP4F2
SCHEMBL23390475 0.80 SMN1; SMN2 (0.36) SMN1; SMN2USP2NR1H2ADORA1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155666-A1 AZETIDINE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN E2 ANTAGONISTS Pfizer Limited (GB) 2010-02-24 EP disclosed
WO-2008139287-A1 AZETIDINE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER LIMITED (GB) 2008-11-20 WO disclosed
WO-2008139287-A1 AZETIDINE DERIVATIVES AND THEIR USE AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER LIMITED (GB) 2008-11-20 WO disclosed
US-20080280877-A1 Azetidines PFIZER INC 2008-11-13 US disclosed
US-20080280877-A1 Azetidines PFIZER INC 2008-11-13 US disclosed
US-20080280877-A1 Azetidines PFIZER INC 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280877-A1 Azetidines PTGER2, PTGER1, PTGDR2 SMN1; SMN2 3965/4885USP2 1293/4885NR1H2 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.